KRISTINA JIMENEZ: Open Payments
NPI 1952776023 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,392 in 130 payments from 21 companies in 2025. Trend: 2023 $679 · 2024 $2,761 · 2025 $2,392
Food & beverage: $2,392
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $462 |
| Janssen Biotech, Inc. | 16 | $385 |
| Aimmune Therapeutics, Inc. | 20 | $228 |
| Ardelyx, Inc. | 8 | $227 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $164 |
| Gilead Sciences, Inc. | 7 | $120 |
| Madrigal Pharmaceuticals | 4 | $115 |
| Ipsen Biopharmaceuticals, Inc | 4 | $114 |
| GENZYME CORPORATION | 3 | $79 |
Products named: TREMFYA, IBSRELA, VOWST, XIFAXAN, RINVOQ, LINZESS, ENTYVIO, REZDIFFRA.
Industry payments across AZ — which companies pay providers there.
